Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cabaletta Bio

1.44
-0.0800-5.26%
Post-market: 1.500.0599+4.16%19:59 EDT
Volume:944.36K
Turnover:1.39M
Market Cap:129.52M
PE:-0.56
High:1.55
Open:1.52
Low:1.43
Close:1.52
Loading ...

Cabaletta Bio price target raised to $25 from $23 at Guggenheim

TIPRANKS
·
16 May

BRIEF-Cabaletta Bio Announces 2027 Rese-Cel BLA Submission Anticipated In Myositis Following Recent FDA Alignment On Registrational Cohorts

Reuters
·
15 May

Cabaletta Bio Inc. Unveils Corporate Presentation on Pioneering Cellular Therapies for Autoimmune Diseases

Reuters
·
15 May

Cabaletta Bio Inc expected to post a loss of 64 cents a share - Earnings Preview

Reuters
·
09 May

Cabaletta Bio’s Clinical Progress and Strategic Direction Bolster Buy Rating

TIPRANKS
·
02 Apr

UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating

MT Newswires Live
·
01 Apr

Cabaletta Bio Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
01 Apr

Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Apr

Cabaletta Bio price target lowered to $7 from $10 at UBS

TIPRANKS
·
01 Apr

Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating

TIPRANKS
·
01 Apr

Cabaletta Bio price target lowered to $13 from $26 at Stifel

TIPRANKS
·
01 Apr

Cabaletta Bio Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
31 Mar

Cabaletta Bio Q4 2024 GAAP EPS $(0.65) Misses $(0.63) Estimate, Operational Runway Into 1H26 With Cash And Cash Equivalents Of $164M As Of December 31, 2024

Benzinga
·
31 Mar

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire
·
31 Mar

Cabaletta Bio and Cellares complete TAP for rese-cel using Cell Shuttle

TIPRANKS
·
19 Mar

Cabaletta Bio Inc expected to post a loss of 64 cents a share - Earnings Preview

Reuters
·
17 Mar

Promising Clinical Advances and Strategic Developments Justify Buy Rating for Cabaletta Bio

TIPRANKS
·
19 Feb

Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Feb

Cabaletta Bio’s Promising Clinical Progress and Strong Buy Rating by Douglas Tsao

TIPRANKS
·
19 Feb

BRIEF-Cabaletta Bio Announces Updated Clinical Data With Rese-Cel At February Scientific Meetings

Reuters
·
18 Feb